Hui Feng

Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial

Zixian Wang, Chengxu Cui, Jun Yao et al. · Cancer Cell · 2022 · 565 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432

F. Wang, Xiaoli Wei, Fenggong Wang et al. · Annals of Oncology · 2019 · 476 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial

Hai-Qiang Mai, Qiu-Yan Chen, Dongping Chen et al. · Nature Medicine · 2021 · 403 citations

Medicine, Oncology, Pharmacology +6

A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy

John Y. Li, Samuel R. Perry, Vanessa Muniz‐Medina et al. · Cancer Cell · 2016 · 390 citations · Full text

Medicine, Oncology, Pharmacology +14

Activated ALK Collaborates with MYCN in Neuroblastoma Pathogenesis

Shizhen Zhu, Jeong-Soo Lee, Feng Guo et al. · Cancer Cell · 2012 · 366 citations · Full text

Medicine, Cancer Biology, Oncology +14